Neurotrauma: A Comprehensive Textbook on Traumatic Brain Injury and Spinal Cord Injury
Autor Kevin K. W. Wangen Limba Engleză Hardback – 20 dec 2018
Preț: 1115.93 lei
Preț vechi: 1395.11 lei
-20% Nou
Puncte Express: 1674
Preț estimativ în valută:
213.57€ • 225.31$ • 177.98£
213.57€ • 225.31$ • 177.98£
Carte disponibilă
Livrare economică 02-07 decembrie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780190279431
ISBN-10: 0190279435
Pagini: 528
Dimensiuni: 282 x 221 x 28 mm
Greutate: 1.75 kg
Editura: Oxford University Press
Colecția OUP USA
Locul publicării:New York, United States
ISBN-10: 0190279435
Pagini: 528
Dimensiuni: 282 x 221 x 28 mm
Greutate: 1.75 kg
Editura: Oxford University Press
Colecția OUP USA
Locul publicării:New York, United States
Recenzii
[T]his is an excellent textbook for those with an academic interest in TBI, particularly the research and medical aspects. It provides a unique collection of topics providing a wide overview of research theme across the whole spectrum of TBI and spinal cord injury ... We strongly recommend it.
Notă biografică
Dr. Kevin Wang is the Director of the Program for Neurotrauma, Neuroproteomics & Biomarkers Research and Associate Professor of Emergency Medicine at the University of Florida in Gainesville, Florida, USA. He is also Health Research Neuroscientist and Merit Award Principal Investigator at the Brain Rehabilitation Research Center at the Malcom Randall VA Medical Center (Gainesville, FL). Dr. Wang is a neurotrauma researcher since the late 1990's. He has served as President and Council Member of the National Neurotrauma society, Board Member, Board of Governors of the International Brain Injury Association and Presidium Member of the Academy for Multidisciplinary Neurotraumatology. His research focus is translational research for traumatic brain injury, spinal cord injury, post-traumatic epilepsy, and chronic traumatic encephalopathy. Two acute TBI blood-based protein biomarkers he co-discovered at University of Florida have now been clinically validated.In 2018, these two TBI biomarkersreceived FDA approval as the first-in class in vitro diagnostic tests for detecting cranial CT abnormality in TB patients.